# Paradigm4

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paradigm4

- Industry: Software
- Headquarters: Waltham, US
- Website: www.paradigm4.com
- Latest round: Series A (Nov 1, 2015)
- Investors on record: 2

## About

Paradigm4 Inc. is a provider of advanced analytics solutions focused on enabling scientific research and optimizing complex biological data analysis for clients across academic, biotech, and pharmaceutical sectors.Founded in 2009 and headquartered in Waltham, US, Paradigm4 specializes in delivering analytics solutions that support scientific research. The company has raised USD 32.50 mn through funding rounds, with its most recent deal occurring on November 1, 2015. Marilyn Matz, who serves as both Founder and CEO, has led the company in its development of technology to help researchers efficiently scale their work without incurring high operational costs.Paradigm4 specializes in delivering advanced analytics solutions designed to empower scientific research and streamline complex biological data analysis. The company's core offerings include tech-enabled services that integrate powerful scientific tools, aimed at helping researchers scale their scientific endeavors effectively without significantly increasing their operational costs. These solutions are tailored for a diverse clientele, including academic institutions, biotech firms, and pharmaceutical companies engaged in cutting-edge research across various disciplines. Paradigm4's products are utilized primarily in North America and Europe, where there is a growing demand for sophisticated analytic capabilities to interpret large volumes of biological data. The company positions itself as a partner in the scientific community, enabling organizations to derive actionable insights from their data, thereby enhancing innovation and discovery in life sciences.Paradigm4 generates revenue through a structured model that includes subscriptions and partnerships with its clients. The company provides its flagship scientific power tools as part of a subscription-based service, where clients pay a recurring fee for access to its analytics platform and associated support services. This model allows clients, such as research institutions and pharmaceutical companies, to leverage the technology for an extended period, ensuring continuous access to updates and new features. The pricing structure typically reflects tiered plans based on the scale of data usage and the number of users, facilitating a tailored fit for organizations of varying sizes and needs. By providing advanced tech-enabled services in a predictable pricing framework, Paradigm4 fosters long-term relationships with its clients, enhancing their research capabilities while ensuring a steady stream of revenue for the company.Paradigm4 is focused on developing new products to enhance its analytics offerings and is strategically planning to expand its market presence in North America and Europe. The recent funding of USD 32.50 mn raised in November 2015 will be utilized to support the design and launch of these new products, which aim to meet the rising demand for advanced data analysis solutions in life sciences. The company’s future initiatives include exploring opportunities for broader geographic expansion to cater to increasing needs in global markets.

## Funding rounds

- Series A, Nov 1, 2015 — Kepha Partners, Golden Seeds

## Investors

- Kepha Partners (https://capitalatlas.ai/funds/kepha-partners) — Series A
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series A